Preetam Shah
Chief Strategy and Financial Officer · Elicio Therapeutics, Inc.
Individual
- 2024
- Jul 17, 2026
- 3
Other insiders active in the same sector
No other insider has filed at Preetam Shah's companies, so these are insiders reporting open-market trades at other companies in the same sector.
- Eric M. Dube - $41.35M in TVTX purchases and sales in the last 12 months
- Jesse J. Geiger - $41.11M in MEDP purchases and sales in the last 12 months
- Mark Hancock - $40.97M in PACS purchases and sales in the last 12 months
- EcoR1 Capital, LLC - $40.00M in AKTS purchases and sales in the last 12 months
- RA CAPITAL MANAGEMENT, L.P. - $40.00M in BCAX purchases and sales in the last 12 months
- Sanj K. Patel - $39.43M in KNSA purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Preetam Shah?
Preetam Shah is a corporate insider, tracked as Chief Strategy and Financial Officer of Elicio Therapeutics, Inc. (ELTX). InsiderAlpha holds 3 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Preetam Shah submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
